GT Biopharma, Inc.
Pharmaceutical Preparations · SAN FRANCISCO · CA
Moderate confidence (50%)
Updated Oct 19, 2026, 12:04 AM
What is happening
Derived by rule set status-rules-2026.09.7
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
Latest material event: GT Biopharma, Inc. received a delisting notice from its exchange (May 20, 2026)
Timeline
Every material event, newest first. History is never overwritten.
GT Biopharma, Inc. received a delisting notice from its exchange
May 20, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. On May 20, 2026, GT Biopharma, Inc., a Delaware corporation (the Company ), received a letter from the Nasdaq Listing Qualifications Staff (the Staff ) of The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that the Staff has granted the Company an additional compliance period of 180 calendar days, or until November 16, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share (the Minimum Bid Price Requirem…”
Company information
- Founded
- —
- Employees (estimate)
- —
- Industry
- Pharmaceutical Preparations
- Subindustry
- —
- Listing
- SEC lists the ticker GTBP on Nasdaq.
- SEC CIK
- 0000109657
- Website
- —
- —
- Headquarters
- SAN FRANCISCO, CA
- Also known as
- GT Biopharma, Inc., OXIS INTERNATIONAL INC
- Legal entities
- GT Biopharma, Inc.
Sources
Every material source used to build this profile.
SEC Company Submissions (TIER 1 · UNVERIFIED)
GT Biopharma, Inc. — Pharmaceutical Preparations (SIC 2834) — SAN FRANCISCO, CA
View source recordSEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. On May 20, 2026, GT Biopharma, Inc., a Delaware corporation (the Company ), received a letter from the Nasdaq Listing Qualifications Staff (the Staff ) of The Nasdaq Stock Market LLC ( Nasdaq ) notifying the Company that the Staff has granted the Company an additional compliance period of 180 calendar days, or until November 16, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share (the Minimum Bid Price Requirem…
View source record
Status history
Every derived status, with the rule that produced it.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:29 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:15 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:32 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 14, 2026, 04:45 PM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
- UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 04:44 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.